Subsequently, we assessed the impact of OSA on metabolic parameters such as Insulin resistance and β-cell function and we investigated the possible role of lipolysis—a proven drug target representing a novel treatment option for OSA-associated metabolic impairments5. This evidence concerns the gene INS and obstructive sleep apnea syndrome.